CNCR
Loncar Cancer Immunotherapy ETFCNCR Fund Description
CNCR tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.
CNCR Factset Analytics Insight
CNCR takes a novel approach to niche coverage within the health care sector. It provides equal- weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting the securities draws attention to smaller companies with room to grow. While it’s still too soon to access performance, this fund provides a unique option for investors placing a highly specialized bet on this space.
CNCR MSCI ESG Analytics Insight
Loncar Cancer Immunotherapy ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.29 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Loncar Cancer Immunotherapy ETF ranks in the 23th percentile within its peer group and in the 25th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
CNCR Charts And Performance
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
CNCR Summary Data
CNCR Portfolio Data
CNCR Index Data
CNCR Portfolio Management
CNCR Tax Exposures
CNCR Fund Structure
CNCR Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 3 out of 5.
CNCR Tradability
CNCR Sector/Industry Breakdown
CNCR
CNCR Top 10 Holdings[View All]
CNCR Countries
CNCR
CNCR Regions
CNCR
CNCR Economic Development
CNCR
CNCR Performance Statistics
CNCR MSCI ESG Ratings
CNCR Benchmark Comparison Summary
CNCR
CNCR Benchmark Comparison Market Cap Size
CNCR
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.